NLNK

Newlink Genetics Corporation

A clinical-stage biopharmaceutical company that worked to harness the immune system against cancer, developing IDO pathway inhibitors like indoximod and the HyperAcute vaccine platform. Founded in 1999 in Ames, Iowa, by Dr. Charles Link and Nicholas Vahanian, the name "NewLink" is a play on its founder's surname. It also drew attention for a high-profile collaboration on an Ebola vaccine before merging into Lumos Pharma in 2020.